Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Advances in Clinical Genomics Profiling » FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

May 06, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

CMS Letter to Orig3n

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

And After the Test

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

Faster, But Not Fast Enough

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

PLOS Papers on Plasmodium vivax Variation in Ethiopia, Childhood BMI Loci, More

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test

  2. Coronavirus Testing Specimen Collection Devices From DNA Genotek, Clinical Enterprises Get FDA EUAs

  3. FDA Relaxes Rules for Flu, RSV Molecular Tests During Coronavirus Health Emergency

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.